
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Sequencing Agents for the Treatment of Pancreatic NETs
Author(s)Pamela L. Kunz, MD
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Advertisement
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Learn more about research into the treatment of pancreatic NETs > >
Articles in this issue
over 11 years ago
Unanswered Questions Regarding the Treatment of Pancreatic NETsover 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsover 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsover 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationover 11 years ago
Coping With Comorbidities in Hepatocellular Cancerover 11 years ago
Strategies in Surveillance: Hepatocellular Carcinomaover 11 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































